147 related articles for article (PubMed ID: 38463590)
1. Complex phenotypic heterogeneity of combined hepatocellular-cholangiocarcinoma with a homogenous
Ohni S; Yamaguchi H; Hirotani Y; Nakanishi Y; Midorikawa Y; Sugitani M; Nakayama T; Makishima M; Esumi M
Am J Transl Res; 2024; 16(2):690-699. PubMed ID: 38463590
[TBL] [Abstract][Full Text] [Related]
2. Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer.
Ohni S; Yamaguchi H; Hirotani Y; Nakanishi Y; Midorikawa Y; Sugitani M; Naruse H; Nakayama T; Makishima M; Esumi M
Oncol Lett; 2022 Jan; 23(1):22. PubMed ID: 34868359
[TBL] [Abstract][Full Text] [Related]
3. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
4. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
5. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
[TBL] [Abstract][Full Text] [Related]
8. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma.
Yang X; Chang J; Li R; Qi Y; Zeng X; Wang W; Li H
J Hepatocell Carcinoma; 2023; 10():113-122. PubMed ID: 36727035
[TBL] [Abstract][Full Text] [Related]
11. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
12. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
13. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
14. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.
Wakizaka K; Yokoo H; Kamiyama T; Kakisaka T; Ohira M; Tani M; Kato K; Fujii Y; Sugiyama K; Nagatsu A; Shimada S; Orimo T; Kamachi H; Matsuoka R; Taketomi A
Hepatol Res; 2020 Feb; 50(2):258-267. PubMed ID: 31661725
[TBL] [Abstract][Full Text] [Related]
15. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
[TBL] [Abstract][Full Text] [Related]
16. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
[TBL] [Abstract][Full Text] [Related]
19. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
20. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.
Raevskaya O; Appelman H; Razumilava N
Curr Hepatol Rep; 2020 Dec; 19(4):478-485. PubMed ID: 33415066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
